Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

v3.20.1
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Current assets    
Cash and cash equivalents $ 86,429 $ 50,412
Marketable securities - available-for-sale debt securities 110,000 39,130
Other current assets and prepaid expenses (including current portion of clinical materials) 31,332 30,947
Total current assets 227,761 120,489
Restricted cash 4,331 4,496
Clinical materials 2,611 2,503
Operating lease right-of-use assets, net of accumulated amortization 19,498 20,789
Property, plant and equipment, net of accumulated depreciation of $24,274 (2019: $23,649) 28,674 31,068
Intangibles, net of accumulated amortization 2,366 2,198
Total assets 285,241 181,543
Current liabilities    
Accounts payable 7,066 6,357
Operating lease liabilities, current 2,590 2,493
Accrued expenses and other accrued liabilities 18,502 23,363
Deferred revenue, current 1,658 2,128
Total current liabilities 29,816 34,341
Operating lease liabilities, non-current 21,829 22,966
Deferred revenue, non-current 46,974  
Other liabilities, non-current 585 598
Total liabilities 99,204 57,905
Stockholders' equity    
Common stock - Ordinary shares par value 0.001, 785,857,300 authorized and 780,514,340 issued and outstanding (2019: 785,857,300 authorized and 631,003,568 issued and outstanding) 1,139 943
Additional paid in capital 678,319 585,623
Accumulated other comprehensive loss (9,590) (7,264)
Accumulated deficit (483,831) (455,664)
Total stockholders' equity 186,037 123,638
Total liabilities and stockholders' equity $ 285,241 $ 181,543